AERO-DINAMICSFOUNDERS | RECENT EVENTS

Committees

• Past-President, American Laryngological Society
• Past-President, American Bronchoesophagological Association

Advisory Committees

• Allergan, Inc Cosmetic Botulinum toxins and injectable fillers
• Merz Pharmaceuticals - Botulinum toxins for Therpeutic Indications
• Revance Pharmaceuticals- Botulinum toxins for cosmetic indications
• Lisa Lasers- Thullium lasers for rhinologic and laryngologic indications

Recent Book Publications

• Neurologic Disorders of the Larynx- 2nd edition, Thieme Medical Publishers
• Botulinum Neurotoxin for Head and Neck Disorders, Thieme Medical Publishers

Invited Speaker

• International Voice Symposium
• Seoul Korea, 2012

Visiting Professor/Lectures

• The Blanchard-Kleinman Lecturer
• University of Maryland, June, 2009
• The Goldman/Biller Lecturer
• Mt. Sinai School of Medicine, June 2009
• The Steven Gray Memorial Lecture
• The University of Utah, June 2009
• The J. Floyd Kyser, MD Lecturer
• The University of Arkansas, June, 2011
• The 2nd Clyde B Alley Lecturer
• Vanderbilt University, December 2011

Faculty

• International Laser in Laryngology Symposium Paris, France April 2010

Guest Faculty

• European Dystonia Meeting Hanover, Germany May 2010

Faculty

• World Voice Meeting Seuol, Korea August 2010

Faculty

• Laryngology and Voice Surgery Harvard Medical School, Boston, September, 2010.

Currently running Research Projects:

• Co- Investigator Double-Blind, placebo controlled study of the use Botox (Botulinum toxin A) for the management of Trigeminal Neuraligia 2006 to 2011 PI- David Sirois, DDS, PhD (NYU)
• Co-Investigator DNA analysis for spontaneous mutations in Idiopathic focal dystonia PI- Mark LeDoux, MD, PhD (U. Tenn-Memphis)
• Co-Investigator Merz Pharmaceuticals Prospective, double-blind, placebo controlled, randomized, multi-center trial with open-label Extension Period to investigate the efficacy and safety of different doses of NT 201 in the treatment of blepharospasm 2007 to 2009.
• Co-Investigator Revance Therapeutics Prospective, double-blind, placebo controlled, randomized trial of a polypeptide-botulinum toxin complex for the management of lateral canthal lines 2008-2010
• Principle Investigator 25 year DataBase for Botulinum toxin therapy safety and efficacy- Unrestricted Research Funding- Allergan, Inc 2011 to present
• Principle Investigator Prospective, double-blind, placebo controlled, randomized trial of Xeomin (Botulinum toxin A)for the Treatment of Subjects with Painful Temporomandibular Disorders (TMD) Unrestricted Research Funding- Merz Pharmaceuticals 2011 to present
• Co-Investigator Dystonia Coalition Projects - Spasmodic Dysphonia Christy Ludlow, PhD and Buzz Jinnah, MD, PhD Principle Investigators